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ABSTRACT 
Purpose 
Urinary continence is a driver of quality of life after radical prostatectomy. The purpose of this 
study was to evaluate the impact of a biologic bladder neck sling on postoperative return of 
urinary continence after robot-assisted radical prostatectomy (RARP). 
Materials and Methods 
This study compared early continence in patients undergoing RARP with a sling and without a 
sling in a two group, 1:1, parallel, randomized controlled trial. Patients were blinded to group 
assignment. The primary outcome was defined as urinary continence (0-1 pads per day) at 1 
month postoperative. Inclusion criteria included organ-confined prostate cancer and a prostate-
specific antigen <15. Exclusion criteria included any prior surgery on the prostate, history of 
neurogenic bladder, and history of prior pelvic radiation. A chi-squared test was used for the 
primary outcome. 
Results 
A total of 147 patients were randomized (control=74, sling=73), and 92% were available for 
primary endpoint analysis at 1 month. There were no significant differences in baseline or 
perioperative data except that operating room time was 20.1 minutes longer for the sling group 
(P=0.04). The continence rate was similar between control and sling groups at both 1 month 
(47.1% vs. 55.2%, P=0.34) and 12 months (86.7% vs. 94.5%, P=0.15), respectively. Adverse 
events were similar between control and sling groups (10.8% vs. 13.7%, P=0.59).  
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Conclusions 
The application of an absorbable urethral sling at the time of RARP was well tolerated with no 
increase in obstructive symptoms in this randomized trial. However, the sling failed to show a 
significant improvement in continence.  
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INTRODUCTION  
Incontinence remains a primary deterrent to the surgical management of prostate cancer, despite 
technological advancements such as robot-assisted laparoscopic radical prostatectomy (RARP). 
Researchers have found urinary control to be a driver of quality of life after radical 
prostatectomy.1 Late post-prostatectomy continence rates in expert hands are high (76-92%)2, 3; 
however, early continence rates are routinely lower and vary widely (32-84%).2, 4 
Efforts to improve post-prostatectomy continence include maximizing urethral length,5 using 
nerve-sparing techniques,6 and preserving or recreating urethral support through reconstructive 
techniques.2, 7-10 The use of a sling for suspension of the vesicourethral anastomosis at the time of 
prostatectomy has shown early promise, but has rarely been studied.11-13 Using an absorbable 
sling material, such as porcine small intestinal submucosa (SIS), could promote early return of 
continence. SIS has all cellular components mechanically removed, leaving a biologic scaffold 
for tissue remodeling. Growth factors, such as fibroblast growth factor-2, are present to support 
the remodeling process.14 The purpose of this trial was to prospectively evaluate the impact of an 
absorbable SIS sling on urinary continence at 1 month and up to 1 year after RARP. 
MATERIALS AND METHODS 
Study design 
This study compared early continence in patients undergoing RARP with or without sling 
placement in a two-group, 1:1, parallel, superiority, randomized controlled trial. One of three 
surgeons at a tertiary care institution or a single surgeon at a private hospital performed the 
procedures. All surgeons were well beyond their learning curve with more than 5 years of 
experience at the start of the trial. The institutional review board (IRB) at both institutions 
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approved the study protocol. The Health Insurance Portability and Accountability Act and the 
Declaration of Helsinki were followed for all study-related procedures and correspondence. 
Funding was provided by the study sponsor, Cook Incorporated. The ClinicalTrials.gov identifier 
for the study is NCT00937833. 
All patient data were entered by site-specific study coordinators into a secure web-based 
electronic case report form system. Access to the system required unique login names and 
passwords. Adverse events were monitored by MED Institute, Inc. and reported to the respective 
IRB and manufacturer according to normal reporting practice for the participating institutions. 
For inclusion and exclusion criteria, see Table 1. Randomization was performed by a 
computerized random number generator and revealed to the surgeon prior to surgery. Patients 
were blinded to the presence or omission of the sling.  
Surgical technique 
A robot-assisted transperitoneal radical prostatectomy technique was used as described 
previously.15 The decision to proceed with a nerve-sparing procedure was generally made prior 
to the operative day and based on patient-reported erectile function and tumor pathology results 
including location of positive biopsy cores.  All prostatectomy steps were identical in the control 
and sling groups. In the sling group, the Cook Biodesign® Surgisis® Urethral Sling was laid 
posterior to the urethra and bladder neck prior to anastomosis, and one end of the sling was 
sutured to the ipsilateral Cooper’s ligament.  After the anastomosis was complete, the other end 
of the sling was carefully sutured to the periosteum of Cooper’s ligament.  Care was taken to 
support the bladder neck but not obstruct it.  The sling was tightened until the first small 
movement of the vesicourethral anastomosis was observed (Figure 1).  No additional 
reconstruction techniques were used in either group. 
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Outcomes 
The primary outcome of the study was continence 1 month after surgery, with continence 
defined as 0-1 pads per day. Secondary outcomes were time to return of continence, obstructive 
symptoms related to the sling, and quality of life related to continence and sexual function at 1, 
3, 6, and 12 months. Quality of life was measured by the Expanded Prostate Cancer Index 
Composite (EPIC) questionnaire.16 The original expanded version (50 questions) was used.  
Obstructive symptoms were assessed by EPIC question 6d. Pain was assessed on postoperative 
day 1 by a patient-reported pain score (0-10). 
Statistics and sample size 
Using retrospective unpublished data, the continence rate at 1 month was hypothesized to be 
84% for the treatment group and 69% for the control. Using α=0.05 and β=0.2, the estimated 
sample size was 251 patients. To account for patients lost to follow-up and study withdrawals, 
total enrollment was intended to be 280 patients. An interim analysis of the primary outcome was 
planned when 126 patients had completed 1-month follow-up using an O'Brien-Fleming 
boundary under futility and efficacy analysis. The interim analysis cutoff for futility was defined 
as P≥0.367 and for efficacy was defined as P≤0.006. The software EAST® 5.5 was used for 
sample size calculations (Cytel, Inc., Cambridge, Massachusetts, USA). Planned triggers to stop 
the study included transient urinary retention >20% or permanent urinary retention >10%. 
Clinically relevant baseline variables were tabulated. Categorical variables were compared using 
chi-squared test. Continuous variables were compared using unpaired t-test. Log rank test was 
used for survival analysis. SAS® 8.2 or higher for Windows® was used for statistical analyses 
(SAS Institute, Inc., Cary, North Carolina, USA). 
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RESULTS 
Recruitment began in November 2009 and ended in October 2013 after the scheduled interim 
analysis showed futility of the primary outcome. Overall, 145/147 patients (99%) treated were 
available for analysis at 1 month, while 117/147 patients (80%) were available through study 
completion at 12 months (Figure 2). There were no significant differences in baseline 
characteristics (Table 2). There were no significant differences in perioperative data, except that 
the operating room time was 20.1 minutes longer for the sling group (P=0.04) (Table 3). Pain 
scores 1 day postoperative were not significantly different between the control and sling groups 
(3.4 vs. 3.5, P=0.74) (Table 3). 
While not statistically significant, the continence rate (0-1 pads) was higher in the sling group 
compared to the control group at both 1 month (55.2% vs. 47.1%, P=0.34) and 12 months 
(94.5% vs. 86.7%, P=0.15) (Table 4, Figure 3).  Of those patients who regained continence 
during the course of the clinical study, the median time to return of continence was 90 days for 
the control group and 77 days for the sling group; this difference was not statistically different 
(P=0.61).  When continence was defined as zero pads per day, the rate was similar between the 
sling (13/67) and the control (13/68) groups (p=0.97) at 1 month.  EPIC scores were similar 
between groups for urinary function (Figure 4), sexual function, and obstructive symptoms 
(Table 4). Finally, the total percentage of patients with adverse events was similar between 
control and sling groups (10.8% vs. 13.7%, P=0.57), respectively (Table 5). The only bladder 
neck contracture occurred in the control group. No adverse events were felt to be “probably” or 
“definitely” related to the sling in the opinion of the principal investigators. 
DISCUSSION 
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Return of continence after RARP remains a primary concern for patients and researchers. In the 
current randomized study, 92% of randomized patients were available for the 1-month primary 
outcome assessment and 79% for the final 12-month follow-up. We found a similar improvement 
in continence rates between 1 and 12 months for the control (47% to 87%) and for the sling 
group (55% to 95%). Due to futility of the primary endpoint calculated at interim analysis, the 
study enrollment was stopped at 147 patients (1-month continence rate, p-value=0.34). 
Importantly, the sling was well-tolerated and total adverse events and obstructive symptoms 
were not increased by sling placement.   
Reports of slings placed at the time of prostatectomy are rare and retrospective in nature, but 
have shown improvements in continence. In 1997, Jorion11 harvested rectus muscle fascia at the 
time of radical retropubic prostatectomy to be used as a sling for the vesicourethral anastomosis. 
Continence was defined as no protection needed at any time. At 1 month, continence improved 
for the sling group and approached statistical significance as compared to the control group (60% 
[18/30] vs. 33% [10/30], P=0.069). At 2 months, continence was significantly improved for the 
sling group as compared to the control group (93% [28/30] vs. 70% [21/30], P=0.04). By 9 
months, continence was 100% (30/30) for the sling group and 93% (28/30) for the control group. 
There was a higher rate of nerve sparing in the sling group. The effect of harvesting fascia on the 
postoperative course was not reported. Early continence rates were higher than in both the 
current study and what is commonly reported in the literature.11 
In 2005, Jones et al12 conducted a small pilot study in which an SIS or a polyglactin sling was 
placed in 15 patients during radical retropubic prostatectomy. Continence was determined based 
on clinic notes rather than on a validated instrument or pad weight. Time to continence (no pads 
needed) was 5.8 weeks for patients in whom slings were placed with no tension and 2.6 weeks 
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when placed with slight tension. When compared to a control group (n=15) at 3 months, 
continence was significantly improved for the sling group (47% [7/15] vs. 93% [14/15], P=0.01). 
The authors concluded the sling was safe and that slight tension on the sling may be beneficial. 
The time to return of continence for the slight tension group was much shorter than the current 
study (2.6 weeks vs. 11 weeks).12 
In 2013, Punnen et al13 reported on the placement of an autologous (vas deferens) retropubic 
urethral sling at the time of RARP. In total, 153 patients had slings placed; these patients were 
compared to 78 patients who did not receive slings. The groups were similar, except the sling 
group was older and underwent fewer nerve-sparing procedures. On multivariate analysis, the 
time to return of continence (no pads) showed an encouraging hazard ratio of 0.77, with a P-
value of 0.20 (95 Confidence Interval: 0.52-1.15). The authors reported a selection bias, as those 
patients with a higher risk of incontinence were more likely to receive a sling. Currently, the 
authors are conducting a randomized trial to assess the effect of the vas deferens sling on urinary 
control; study completion is projected for 2017.17 
One limitation of the current study was a lack of standardization of sling tension. All surgeons 
attempted to apply the sling to support the bladder neck without obstructing it. The tension 
required to achieve this objective was left to the discretion of the surgeon without an objective 
method to measure it.  As the reported obstructive symptoms were very similar between groups, 
it is possible more tension could have been placed on the sling without complication. Future 
studies should use objective measures of sling tension that allow for testing at multiple tension 
values. Another limitation is the prolonged accrual of patients, which took four years. However, 
this is a known difficulty of randomized surgical trials, and the authors do not feel this adversely 
affected the results.  Another limitation is that the surgeons knew the allocation prior to the 
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prostatectomy, which could have resulted in technique changes.  For example, surgeons could 
have theoretically and subconsciously done a better apical dissection for the sling group resulting 
in a confounding variable.  However, this seems unlikely as the surgeons desired optimal patient 
outcomes regardless of group allocation and did not have any financial conflicts of interest 
related to the product.  Finally, the surgeons were well beyond their learning curve and at high 
volume centers, so the results may not be applicable to smaller clinic settings. However, the 
application of a urethral sling at the time of RARP utilizes basic robotic skills, which do not 
require advanced training. 
CONCLUSIONS 
The application of an absorbable vesicourethral sling at the time of robot-assisted laparoscopic 
radical prostatectomy was well tolerated with no increase in obstructive symptoms in this 
randomized trial. However, the sling failed to result in a significant improvement in continence. 
Future studies should assess the effects of differing levels of sling tension on continence and 
adverse events. 
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FIGURES 
 
 Figure 1: The Cook Biodesign® Surgisis® urethral sling (bioabsorbable) was laid across the 
pelvic floor in preparation for the vesicourethral anastomosis (A-B).  After the anastomosis, the 
sling was sutured to Cooper’s ligament on both sides (C-D) with minimal tension to give support 
to the anastomosis. 
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Figure 2: Flowchart for enrollment and follow-up.   
RARP = robot-assisted radical prostatectomy; LTF = lost to follow-up 
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Figure 3: Comparison of continence between the sling and control groups 
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Figure 4: Comparison of EPIC urinary function score for sling and control groups 
EPIC = Expanded Prostate Cancer Index Composite 
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Table 1: Inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
1. Organ confined prostate cancer 
2. PSA <15 
3. Prostate cancer stage <cT3 
4. Scheduled for transperitoneal RARP 
5. Age ≥18 
6. Able to provide written informed 
consent and HIPAA authorization for 
release of personal health information 
1. Any previous surgery to the prostate 
2. Previous incision of urethral stricture or bladder 
neck contracture 
3. Previous diagnosis of urethral stricture, bladder 
neck contracture, or urinary incontinence 
4. Previous diagnosis of atonic or neurogenic 
bladder 
5. Significant preoperative voiding symptoms as 
defined by an AUA-SS of >19 
6. Prior history of radiation to the pelvis 
7. Persistent bacteriuria that cannot be cleared 
8. Allergies to pig tissue or pig products or 
religious or cultural objection to the use of pig 
tissue 
9. Prostate is felt to be too large in the opinion of 
the treating physician 
PSA: Prostate-Specific Antigen; RARP: Robot-Assisted Radical Prostatectomy; HIPAA: Health 
Insurance Portability and Accountability Act; AUA-SS: American Urological Association 
Symptom Score 
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Table 2: Baseline characteristics 
 Control 
N=74 
Sling 
N=73 P-value 
Age, years, Mean ± SD 60.6 ± 7.1 60.9 ± 6.1 0.79 
BMI, kg/m2, Mean ± SD 29.4 ± 4.7 30.0 ± 5.6 0.47 
Smoking status, no. (%) 
   Non-smoker 45 (60.8%) 43 (58.9%) 
0.84    Past smoker 23 (31.1%) 22 (30.1%) 
   Current smoker 6 (8.1%) 8 (11.0%) 
Alcohol consumption, no. (%) 
   None 34 (45.9%) 34 (46.6%) 
0.95    Weekly 25 (33.8%) 23 (31.5%) 
   Daily 15 (20.3%) 16 (21.9%) 
Hypertension, no. (%) 31 (41.9%) 38 (52.1%) 0.22 
Diabetes, no. (%) 9 (12.2%) 11 (15.1%) 0.61 
Urinalysis obtained, no. (%) 73 (98.6%) 71 (97.3%) 0.55 
Bacteriuria preoperative, no. (%) 0 (0%) 1 (1.4%) 0.31 
PSA, ng/mL, Mean ± SD 6.54 ± 4.01 5.88 ± 2.83 0.25 
Gleason score (biopsy), Mean ± SD 6.61 ± 0.74 6.66 ± 0.73 0.68 
Clinical stage   0.27 
   T1b 1 (1.4%) 0  
   T1c 58 (78.4%) 61 (83.6%)  
   T2a 7 (9.5%) 8 (11.0%)  
   T2b 4 (5.4%) 4 (5.5%)  
   T2c 4 (5.4%) 0  
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Table 3: Operative and follow-up data 
 Control 
N=74 
Sling 
N=73 P-value 
Nerve sparing, no. (%) 
   Bilateral 57 (77.0%) 53 (72.6%) 
0.77    Unilateral 7 (9.5%) 7 (9.6%) 
   Non-nerve sparing 10 (13.5%) 13 (17.8%) 
Anastomotic leak intraoperatively, no. (%) 1 (1.4%) 3 (4.1%) 0.3 
Leak on postoperative cystogram, leaks/total 
cystograms performed (%) 2/38 (5.3%) 0/38 (0%) 0.15 
Estimated blood loss, mL, Mean ± SD 147.6 ± 83.6 174.7 ± 129.5 0.13 
Operating time, minutes, Mean ± SD 174.5 ± 51.8 194.6 ± 65.0 0.04 
Intraoperative complications, no. (%)  0 (0%) 0 (0%) - 
Pain score (0-10), postoperative day 1, Mean ± SD 3.4 ± 2.1 3.5 ± 1.9 0.74 
Gleason score (pathology report), Mean ± SD 6.97 ± 0.67 7.18 ± 0.95 0.13 
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Table 4: Primary and secondary outcomesa 
 Control 95% C.I. Sling 95% C.I. P-value 
 Continence, n/N (%) 
   Preoperative 74/74 (100%)  73/73 (100%)  - 
   1 Month 32/68 (47.1%)  37/67 (55.2%)  0.34 
   3 Months 48/65 (73.8%)  49/65 (75.4%)  0.84 
   6 Months 51/59 (86.4%)  50/59 (84.7%)  0.79 
   12 Months 52/60 (86.7%)  52/55 (94.5%)  0.15 
 EPIC score - urinary function, Mean ± SD (N) 
   Preoperative 92.6 ± 9.6 (72) 90.3, 94.9 90.9 ± 11.1 (72) 88.3, 93.5 0.34 
   2 days post cath. 
removal 64.3 ± 21.3 (66) 
59.1, 69.5 66.1 ± 20.7 (62) 60.8, 71.4 0.62 
   1 Month 64.7 ± 18.2 (65) 60.2, 69.2 69.9 ± 18.2 (65) 65.4, 74.4 0.10 
   3 Months 78.9 ± 14.1 (63) 75.3, 82.5 79.8 ± 14.8 (64) 76.1, 83.5 0.73 
   6 Months 87.6 ± 12.2 (58) 84.4, 90.8 86.6 ± 16 (59) 82.4, 90.8 0.71 
   12 Months 88.7 ± 12.1 (59) 85.5, 91.9 89.7 ± 11.9 (54) 86.5, 92.9 0.68 
 EPIC score - sexual function, Mean ± SD (N) 
   Preoperative 61.4 ± 23 (71) 56.0, 66.8  57.9 ± 25 (73) 52.1, 63.7 0.39 
   2 days post 
catheter removal 33.6 ± 25.1 (64) 
27.3, 39.9 32.9 ± 27 (62) 26.0, 39.8 0.88 
   1 Month 27.7 ± 19.5 (65) 22.9, 32.5 26.8 ± 20.3 (65) 21.8, 31.8 0.80 
   3 Months 31.7 ± 19.7 (62) 26.7, 36.7 32 ± 23.1 (63) 26.2, 37.8 0.94 
   6 Months 33.8 ± 17.8 (58) 29.1, 38.5 34.7 ± 23.3 (58) 28.6, 40.8 0.81 
   12 Months 38.6 ± 20.8 (58) 33.1, 44.1 42.5 ± 23 (53) 36.2, 48.8 0.35 
 EPIC score - obstructive symptomsb, Mean ± SD (N) 
   Preoperative 0.6 ± 0.9 (72) 0.4, 0.8 0.8 ± 1.1 (70) 0.5, 1.1 0.37 
   2 days post 
catheter removal 1.2 ± 1.3 (68) 
0.9, 1.5 1.2 ± 1.3 (64) 0.9, 1.5 0.94 
   1 Month 1.1 ± 1.2 (65) 0.8, 1.4 0.9 ± 1.1 (65) 0.6, 1.2 0.32 
   3 Months 0.5 ± 0.8 (64) 0.3, 0.7 0.5 ± 0.9 (64) 0.3, 0.7 0.67 
   6 Months 0.2 ± 0.4 (58) 0.1, 0.3 0.3 ± 0.7 (59) 0.1, 0.5 0.13 
   12 Months 0.2 ± 0.5 (60) 0.1, 0.3 0.3 ± 0.6 (55) 0.1, 0.5 0.83 
 AUA-SS, Mean ± SD (N) 
   Preoperative 7.4 ± 4.3 (55) 6.2, 8.6 8.6 ± 5.6 (55) 7.1, 10.1 0.21 
   2 days post 
catheter removal 12.3 ± 7.5 (39) 
9.9, 14.7 12.1 ± 7.6 (35) 9.5, 14.7 0.92 
   1 Month 11.1 ± 6.2 (45) 9.2, 13.0 11.0 ± 6.3 (46) 9.1, 12.9 0.97 
   3 Months 8.0 ± 4.2 (39) 6.6, 9.4 9.3 ± 5.2 (40) 7.6, 11.0 0.21 
   6 Months 5.9 ± 4.3 (35) 4.4, 7.4 7.0 ± 6.5 (33) 4.7, 9.3 0.40 
   12 Months 5.3 ± 4.6 (30) 3.6, 7.0 7.0 ± 4.6 (27) 5.2, 8.8 0.15 
EPIC: Expanded Prostate Cancer Index Composite; AUA-SS: American Urological Association 
Symptom Score 
a Not all patients reported all data at each time point. Denominators represent number of patients 
with data available for analysis. 
b Taken from EPIC question 6d, “Weak urine stream or incomplete emptying” 
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Table 5: Adverse events 
 Control Sling 
Total adverse events, n/N (%) 8/74 (10.8%) 10/73 (13.7%) 
Did event lead to serious adverse 
event? no. (%) 0/8 (0%) 4/10 (40.0%) 
Related to sling? no. (%) 
   Not related or unlikely 6/8 (75.0%) 6/10 (60.0%) 
   Possibly 0 (0%) 4/10 (40.0%) 
   Probably or definitely 0 (0%) 0/10 (0%) 
Description, no. (%) 
   UTI 4/8 (50.0%) 3/10 (30.0%) 
   Pyonephritis 0/8 (0%) 2/10 (20.0%) 
   Urethral stricture 0/8 (0%) 1/10 (10.0%) 
   Pelvic abscess 0/8 (0%) 1/10 (10.0%) 
   Bladder neck contracture, 
Weck clip erosion 1/8 (12.5%) 0/10 (0%) 
   Drain erosion into anastomosis 0/8 (0%) 1/10 (10.0%) 
   Bladder spasm 2/8 (25.0%) 0/10 (0%) 
   Dysuria 1/8 (12.5%) 0/10 (0%) 
   Mid ureteral stricture 0/8 (0%) 2/10 (20.0%) 
	
 
 
